View in EDS HTML Full Text PDF Full Text

Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors.

Saved in:
Bibliographic Details
Title: Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors.
Authors: Italiano A; Institut Bergonié, Bordeaux, France.; Gustave Roussy, Villejuif, France.; Faculty of Medicine, University of Bordeaux, Bordeaux, France., Miller WH Jr; Segal Cancer Centre, Jewish General Hospital, McGill University, Montreal, QC, Canada., Blay JY; Centre Léon Bérard, Lyon, France., Gietema JA; University Medical Center Groningen, University of Groningen, Groningen, the Netherlands., Bang YJ; Seoul National University College of Medicine, Seoul, South Korea., Mileshkin LR; Peter MacCallum Cancer Center, Melbourne, Australia., Hirte HW; Juravinski Cancer Centre, Hamilton, ON, Canada., Higgins B; Roche Innovation Center, Hoffmann-La Roche, New York, NY, USA., Blotner S; Roche Innovation Center, Hoffmann-La Roche, New York, NY, USA., Nichols GL; Roche Innovation Center, Hoffmann-La Roche, New York, NY, USA., Chen LC; Roche Innovation Center, Hoffmann-La Roche, New York, NY, USA., Petry C; Roche Innovation Center, Basel, Switzerland., Yang QJ; Certara, Montréal, QC, Canada., Schmitt C; Roche Innovation Center, Basel, Switzerland., Jamois C; Roche Innovation Center, Basel, Switzerland., Siu LL; Princess Margaret Cancer Centre, Toronto, ON, Canada. lillian.siu@uhn.ca.
Source: Investigational new drugs [Invest New Drugs] 2021 Dec; Vol. 39 (6), pp. 1587-1597. Date of Electronic Publication: 2021 Jun 28.
Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Springer Country of Publication: United States NLM ID: 8309330 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-0646 (Electronic) Linking ISSN: 01676997 NLM ISO Abbreviation: Invest New Drugs Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 34180037
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Italiano+A%22">Italiano A</searchLink>; Institut Bergonié, Bordeaux, France.; Gustave Roussy, Villejuif, France.; Faculty of Medicine, University of Bordeaux, Bordeaux, France.<br /><searchLink fieldCode="AU" term="%22Miller+WH+Jr%22">Miller WH Jr</searchLink>; Segal Cancer Centre, Jewish General Hospital, McGill University, Montreal, QC, Canada.<br /><searchLink fieldCode="AU" term="%22Blay+JY%22">Blay JY</searchLink>; Centre Léon Bérard, Lyon, France.<br /><searchLink fieldCode="AU" term="%22Gietema+JA%22">Gietema JA</searchLink>; University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Bang+YJ%22">Bang YJ</searchLink>; Seoul National University College of Medicine, Seoul, South Korea.<br /><searchLink fieldCode="AU" term="%22Mileshkin+LR%22">Mileshkin LR</searchLink>; Peter MacCallum Cancer Center, Melbourne, Australia.<br /><searchLink fieldCode="AU" term="%22Hirte+HW%22">Hirte HW</searchLink>; Juravinski Cancer Centre, Hamilton, ON, Canada.<br /><searchLink fieldCode="AU" term="%22Higgins+B%22">Higgins B</searchLink>; Roche Innovation Center, Hoffmann-La Roche, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Blotner+S%22">Blotner S</searchLink>; Roche Innovation Center, Hoffmann-La Roche, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Nichols+GL%22">Nichols GL</searchLink>; Roche Innovation Center, Hoffmann-La Roche, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Chen+LC%22">Chen LC</searchLink>; Roche Innovation Center, Hoffmann-La Roche, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Petry+C%22">Petry C</searchLink>; Roche Innovation Center, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Yang+QJ%22">Yang QJ</searchLink>; Certara, Montréal, QC, Canada.<br /><searchLink fieldCode="AU" term="%22Schmitt+C%22">Schmitt C</searchLink>; Roche Innovation Center, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Jamois+C%22">Jamois C</searchLink>; Roche Innovation Center, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Siu+LL%22">Siu LL</searchLink>; Princess Margaret Cancer Centre, Toronto, ON, Canada. lillian.siu@uhn.ca.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%228309330%22">Investigational new drugs</searchLink> [Invest New Drugs] 2021 Dec; Vol. 39 (6), pp. 1587-1597. <i>Date of Electronic Publication: </i>2021 Jun 28.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Springer%22">Springer </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>8309330 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1573-0646 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2201676997%22">01676997 </searchLink><i>NLM ISO Abbreviation: </i>Invest New Drugs <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=34180037
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s10637-021-01141-2
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1587
    Titles:
      – TitleFull: Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Italiano A
      – PersonEntity:
          Name:
            NameFull: Miller WH Jr
      – PersonEntity:
          Name:
            NameFull: Blay JY
      – PersonEntity:
          Name:
            NameFull: Gietema JA
      – PersonEntity:
          Name:
            NameFull: Bang YJ
      – PersonEntity:
          Name:
            NameFull: Mileshkin LR
      – PersonEntity:
          Name:
            NameFull: Hirte HW
      – PersonEntity:
          Name:
            NameFull: Higgins B
      – PersonEntity:
          Name:
            NameFull: Blotner S
      – PersonEntity:
          Name:
            NameFull: Nichols GL
      – PersonEntity:
          Name:
            NameFull: Chen LC
      – PersonEntity:
          Name:
            NameFull: Petry C
      – PersonEntity:
          Name:
            NameFull: Yang QJ
      – PersonEntity:
          Name:
            NameFull: Schmitt C
      – PersonEntity:
          Name:
            NameFull: Jamois C
      – PersonEntity:
          Name:
            NameFull: Siu LL
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 12
              Text: 2021 Dec
              Type: published
              Y: 2021
          Identifiers:
            – Type: issn-electronic
              Value: 1573-0646
          Numbering:
            – Type: volume
              Value: 39
            – Type: issue
              Value: 6
          Titles:
            – TitleFull: Investigational new drugs
              Type: main
ResultId 1